Oncolys BioPharma Inc.
Notice of J-CMA committee meeting on pricing for Telomerasine® Injection
Notice of J-CMA (Japan Central Medical Association) pricing deliberations. It is announced that the pricing for Telomerasine® injection will be deliberated by the J-CMA plenary session, with the impact on the 2026 fiscal year results under review. Commercial launch is planned for the 2026 fiscal year as scheduled.
Key Figures
- Impact on the 2026 fiscal year results: Unknown
- Planned launch timing: 2026 fiscal year (planned)
- Pricing deliberation: to be reviewed at the J-CMA plenary session
AI要約
Key takeaways
OncoCyte Bio-Pharma announced that the pricing deliberation for Telomerasine® Injection (OBP-301) will be held at the J-CMA plenary session. The progression of pricing deliberations and post-approval launch plan are indicated, with the impact on the 2026 fiscal year results undetermined.
Outlook and impact for investors
Revenue contribution from this product will vary depending on the pricing deliberation outcome. At present, the impact amount is unknown, and it is necessary to watch the deliberations and launch progress closely.
OncoCyte Bio-Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
